Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354948 | 0.84 | CNR1 (0.55) | CNR1CA2 | |
| SCHEMBL4238494 | 0.81 | CA2 (0.61) | CNR1CA2 | |
| SCHEMBL8799150 | 0.80 | CNR1 (0.61) | CNR1CA2 | |
| SCHEMBL8983658 | 0.79 | CNR1 (0.56) | CNR1CA2 | |
| SCHEMBL30437414 | 0.78 | CA2 (0.66) | CNR1CA2 | |
| SCHEMBL19559032 | 0.78 | CA2 (0.59) | CNR1CA2 | |
| SCHEMBL11329617 | 0.77 | CA2 (0.56) | CNR1CA2 | |
| SCHEMBL8476923 | 0.77 | CNR1 (0.62) | CNR1CA2 | |
| SCHEMBL6923052 | 0.76 | CA2 (0.54) | CNR1CA2 | |
| SCHEMBL19928719 | 0.76 | CA2 (0.58) | CNR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1335720-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | Bayer Aktiengesellschaft (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6498183-B1 | TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | disclosed |
| WO-2002036115-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1177171-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | Bayer Aktiengesellschaft (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066553-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | HTR6, SLC6A4, AANAT | CNR1 104/4885CA2 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.